Irinotekan Teva

Irinotecan, the active ingredient in Irinotekan Teva, is a topoisomerase I inhibitor presented as an intravenous formulation for use in cancer therapy. It is employed primarily for metastatic colorectal cancer and advanced colorectal adenocarcinoma in adult patients.

GNH USA supplies Irinotekan Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan is a chemotherapy agent used in the treatment of colorectal cancer and related disease states. - Metastatic colorectal cancer: administered as part of combination regimens to improve overall survival. - Advanced colorectal adenocarcinoma: used to reduce tumor burden and delay disease progression. - Colorectal cancer (adjuvant setting): given after surgery to lower the risk of recurrence.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related gastrointestinal upset. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: generalized tiredness during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Severe colitis: intense inflammation of the colon leading to dehydration. - Hepatotoxicity: elevated liver enzymes or jaundice. - Allergic reactions: rash, bronchospasm, or anaphylaxis in rare cases.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for toxicity. - Dose adjustment: consider renal or hepatic impairment when determining the appropriate dose. - Baseline labs: obtain complete blood count and liver function tests prior to each cycle. - Infection risk: advise patients to report fever or signs of infection promptly. - Pregnancy and lactation: avoid use unless the potential benefit justifies the potential risk to the fetus or infant. - Store at ambient temperature: keep in the original container, protect from light and moisture, and do not freeze.

Irinotecan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong UGT1A1 inhibitors (e.g., atazanavir): may increase SN‑38 exposure and toxicity. - Concurrent use of potent CYP3A4 inhibitors (e.g., ketoconazole): can raise irinotecan plasma levels. - Live vaccines: immunosuppression may reduce vaccine effectiveness and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower drug concentrations, reducing efficacy. - Other myelosuppressive agents: combined effect can exacerbate neutropenia. - Radiation therapy: concurrent treatment may increase gastrointestinal toxicity.